Clinical trial
Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer
NCT00176813 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00176813 |
|---|---|
| Title | Gemcitabine, Cisplatin, and Celecoxib Treatment of Metastatic Pancreatic Cancer |
| Official title | Phase II Study of Gemcitabine, Cisplatin, and Celecoxib in the Treatment of Metastatic Pancreatic Cancer |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | Eli Lilly and Company Industry Barbara Ann Karmanos Cancer Institute |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Pancreatic Cancer |
| Intervention type | Drug |
| Interventions | Gemcitabine, Cisplatin, Celecoxib |
| Enrollment | 5 |
| Start date | Mar 1, 2003 |
| Primary completion | Nov 1, 2003 |
| Completion | Nov 1, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | May 6, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: